BCL2 and B-cell chronic lymphocytic leukemia: Although we observed that IVIg preparations did not affect the spontaneous apoptosis of leukemic cells (Fig. 1d, 3c), we asked whether these preparations might affect the apoptosis induced by the BCL-2 inhibitor, venetoclax, currently employed in CLL treatment.